A Phase I/II Study of Lenalidomide in Patients with AIDS-Associated Kaposi's Sarcoma

Protocol
10-116
Full Title
A Phase I/II Study of Lenalidomide in Patients with AIDS-Associated Kaposi's Sarcoma (AMC 070)
Phase
I/II
Purpose

Kaposi’s sarcoma (KS) is a type of cancer that is very common in people with AIDS. Treatments for KS do not cure the disease, and better treatments are needed.

Lenalidomide is used to treat some kinds of blood cancer. In laboratory studies, it stops tumor growth by interfering with the growth of new blood vessels. It also increases the ability of immune cells to kill tumor cells. It has also stopped or slowed the growth of some cancers.

In this study, researchers want to determine the optimal dose of lenalidomide that can be given in people with AIDS-related KS. They also want to see if lenalidomide lowers levels of factors that may make KS tumors grow, and find out what effects it has on immune cells that may help kill KS cells in the body. Investigators want to determine if this drug can make KS tumors shrink or disappear.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have Kaposi’s sarcoma and HIV infection.
  • Patients must have sufficient KS tissue for four biopsies.
  • Patients must have disease that is newly diagnosed or persists despite prior treatment, or patients must be unable to tolerate other treatments.
  • Patients must be taking antiretroviral treatment for HIV.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Mark A. Dickson at 646-888-4166.

Disease(s)
AIDS-Associated Cancers
AIDS-Associated Cancers: AIDS-Associated Kaposi's Sarcoma
Locations
Related Diseases